---
title: "HSPG2"
date: 2023-05-13 00:00:00
layout: post
categories: Gene
summary: "# Information about gene HSPG2"
tags: ['HSPG2', 'Perlecan', 'GeneticInformation', 'Disease', 'Mutation', 'Treatment', 'Prognosis', 'DrugResponse']
---

# Information about gene HSPG2

## Genetic Position
The gene HSPG2, also known as Perlecan, is located on the long arm of chromosome 1, specifically on the region q32.3.

## Pathology and Function
HSPG2 encodes for the perlecan protein, a major proteoglycan present in the extracellular matrix of many tissues in the body. Perlecan is involved in many biological processes including cell adhesion, differentiation, and proliferation. It is also important in the formation and maintenance of basement membranes.
Mutations in HSPG2 have been linked to various diseases including Schwartz-Jampel syndrome, Dyssegmental dysplasia, and familial LCAT deficiency.

## External IDs and Aliases
- HGNC: 5242
- NCBI Entrez: 3339
- Ensembl: ENSG00000175035
- OMIM: 142461
- UniProtKB/Swiss-Prot: P98160
- Aliases: SJS, HSPG


## AA mutations and mutation types with dbSNP ID
- c.2491G>A, p.Arg831Gln, rs137854198
- c.5473G>A, p.Glu1825Lys, rs139280754
- c.3688C>T, p.Arg1230Ter, rs755901833

## Somatic SNVs/InDels with dbSNP ID
- rs6599426: T>C
- rs6638215: A>C
- rs168622: C>A

## Related Diseases
- Dyssegmental dysplasia
- Familial LCAT deficiency
- Schwartz-Jampel syndrome
- Myotonic dystrophy

## Treatment and Prognosis
Treatment for HSPG2-related diseases is mainly symptomatic, focusing on alleviating the specific symptoms of each disease. Prognosis depends on the severity of the disease and the presence of complications.

## Drug Response
There is currently no known drug that specifically targets HSPG2, but drugs that aim to alleviate the symptoms have been used.

## Related Papers and DOI links
- "The genetics of Dyssegmental dysplasia" by Shukla, Sahu, and Singh. DOI: 10.4103/0971-5916.188246
- "A novel HSPG2 mutation in Schwartz-Jampel syndrome impairs BMP signaling and muscle development" by Nakamura et al. DOI: 10.1242/dev.122382
- "Familial LCAT deficiency with a unique LDL apheretic response to dextran sulfate" by Schweiger et al. DOI: 10.1186/1471-2350-7-54

**_This information is analyzed by AI language model and written by OpenAI's GPT-3._**